RGLAX
Price
$23.40
Change
-$0.65 (-2.70%)
Updated
Dec 18 closing price
RWIBX
Price
$62.66
Change
-$1.77 (-2.75%)
Updated
Dec 18 closing price
Ad is loading...

RGLAX vs RWIBX

Header iconRGLAX vs RWIBX Comparison
Open Charts RGLAX vs RWIBXBanner chart's image
American Funds Global Insight R-1
Price$23.40
Change-$0.65 (-2.70%)
VolumeN/A
CapitalizationN/A
American Funds Capital World Gr&Inc R2
Price$62.66
Change-$1.77 (-2.75%)
VolumeN/A
CapitalizationN/A
RGLAX vs RWIBX Comparison Chart
Loading...
View a ticker or compare two or three
VS
RGLAX vs. RWIBX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGLAX is a StrongBuy and RWIBX is a Buy.

FUNDAMENTALS
Fundamentals
RWIBX has more cash in the bank: 121B vs. RGLAX (15.4B). RWIBX pays higher dividends than RGLAX: RWIBX (1.05) vs RGLAX (0.74). RGLAX was incepted earlier than RWIBX: RGLAX (5 years) vs RWIBX (23 years). RWIBX is a more actively managed with annual turnover of: 27.00 vs. RGLAX (23.00). RGLAX (250) and RWIBX (250) have matching initial minimum investment requirements. RGLAX annual gain was more profitable for investors over the last year : 14.00 vs. RWIBX (11.34). RGLAX return over 5 years is better than : 46.24 vs. RWIBX (29.64).
RGLAXRWIBXRGLAX / RWIBX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence5 years23 years-
Gain YTD12.6189.781129%
Front LoadN/AN/A-
Min. Initial Investment250250100%
Min. Initial Investment IRAN/AN/A-
Net Assets15.4B121B13%
Annual Yield % from dividends0.741.0571%
Returns for 1 year14.0011.34123%
Returns for 3 years15.288.41182%
Returns for 5 years46.2429.64156%
Returns for 10 yearsN/A44.22-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LITM0.180.03
+17.46%
Snow Lake Resources Ltd
NUVB2.810.12
+4.46%
Nuvation Bio
ENTG109.362.65
+2.48%
Entegris
ARQ7.01-0.04
-0.57%
Arq
PTCT47.02-1.59
-3.27%
PTC Therapeutics